Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder

Annals of Pharmacotherapy

Volumn 48, Issue 8, 2014, Pages 1030-1039

  Palmer, Emma C ^a   Binns, Lindsey N ^b   Carey, Heather ^c  

^a Sullivan University College of Pharmacy   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

antidepressants; central nervous system; depression; psychiatry; serotonin

Indexed keywords

ACETYLSALICYLIC ACID; BUSPIRONE; CARBAMAZEPINE; CLARITHROMYCIN; DESVENLAFAXINE; DULOXETINE; FENTANYL; HERBACEOUS AGENT; KETOCONAZOLE; LINEZOLID; LITHIUM; METHYLENE BLUE; MILNACIPRAN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENELZINE; PLACEBO; RIFAMPICIN; RITONAVIR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; TRYPTOPHAN; VENLAFAXINE; WARFARIN;

COCHRANE LIBRARY; CONSTIPATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; GERIATRICS; HEADACHE; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERICUM PERFORATUM; HYPERTENSION; HYPOMANIA; KIDNEY DYSFUNCTION; LACTATION; LIVER DYSFUNCTION; MAJOR DEPRESSION; MANIA; MEDLINE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NONHUMAN; PATIENT COUNSELING; PATIENT MONITORING; PEDIATRICS; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SCROTAL PAIN; SEROTONIN SYNDROME; SEX DIFFERENCE; SUICIDAL IDEATION; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION; URINE RETENTION; VOMITING; WITHDRAWAL SYNDROME;

EID: 84904511898     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014535074     Document Type: Review

References (40)

1. Kessler RC,Petukhova M,Sampson NA,Zaslavsky AM,Wittchen HU.Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States.Int J Methods Psychiatr Res. 2012;21:169-184.
2. Rihmer Z,Gonda X.Pharmacological prevention of suicide in patients with major mood disorders.Neurosci Biobehav Rev. 2013;37:2398-2403.
3. Abelaira HM,Reus GZ,Quevedo J.Animal models as tools to study the pathophysiology of depression.Rev Bras Psiquiatr. 2013;35:S112-S120.
4. Blier P,Briley M.The noradrenergic symptom cluster: clinical expression and neuropharmacology.Neuropsychiatr Dis Treat. 2011;7:15-20.
5. Guiard BP,Mansari ME,Merali Z,Blier P.Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions.Int J Neuropsychopharmacol. 2008;11:625-639.
6. HayleySLittlejohnD. Neuroplasticity and the next wave of antidepressant strategies. Front Cell Neurosci. 2013;7:218. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834236/. Published November 20, 2013. Accessed December 12, 2013.
7. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 3rd ed.Arlington, VA: American Psychiatric Association; 2010.Arlington, VA: American Psychiatric Association; 2010:.
8. Fetzima (levomilnacipran) [package insert].St Louis, MO: Forest Laboratories; 2013:.
9. Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke: a multicenter, randomized, double-blind, parallel-group, placebo-controlled study. http://clinicaltrials.gov/show/NCT01639014. Accessed April 30, 2014.
10. Auclair AL,Martel JC,Assie MD,et al.Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.Neuropharmacology. 2013;70:338-347.
11. St Louis, MO: Forest Laboratories Inc; 2013:.
12. Montgomery S,Briley M.Milnacipran: recent findings in depression.Neuropsychiatr Dis Treat. 2010;6:1-2.
13. Effexor XRPhiladelphia, PA: Pfizer Wyeth Pharmaceuticals Inc; 2012:.
14. Dayton, NJ: Aurobindo Pharma USA; 2013:.
15. Philadelphia, PA: Pfizer Wyeth Pharmaceuticals Inc; 2013:.
16. Deecher DC,Beyer CE,Johnston G,et al.Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor.J Pharmacol Exp Ther. 2006;318:657-665.
17. Spring Valley, NY: Par Pharmaceutical Companies, Inc; 2013:.
18. Indianapolis, IN: Eli Lilly & Company; 2012:.
19. Sharma A,Goldberg MJ,Cerimele BJ.Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.J Clin Pharmacol. 2000;40:161-167.
20. Tamiya J,Dyck B,Zhang M,et al.Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.Bioorg Med Chem Lett. 2008;18:3328-3332.
21. Asnis GM,Bose A,Gommoll CP,Chen C,Greenberg WM.Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.J Clin Psychiatry. 2013;74:242-248.
22. Bakish D,Gommoll C,Chen C,et al.Levomilnacipran SR 40 mg and 80 mg in major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. Paper presented at: 51st Annual Meeting of the American College of Neuropsychopharmacology; Hollywood, FL.
23. Sambunaris A,Bose A,Gommoll C,et al.Phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran SR in patients with major depressive disorder. Paper presented at: 51st Annual Meeting of the American College of Neuropsychopharmacology; Hollywood, FL.
24. Renoir T.Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved.Front Pharmacol. 2013;4:45.
25. Citrome L.Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?.Int J Clin Pract. 2013;67:1089-1104.
26. Ramsay RR,Dunford C,Gillman PK.Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.Br J Pharmacol. 2007;152:946-951.
27. Quinn DK,Stern TA.Linezolid and serotonin syndrome.Prim Care Companion J Clin Psychiatry. 2009;11:353-356.
28. Volpi-Abadie J,Kaye AM,Kaye AD.Serotonin syndrome.Ochsner J. 2013;14:533-540.
29. US National Library of Medicine. Drugs and Lactation Database (LactMed). Bethesda, MD: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed February 26, 2014.
30. Alipour A.STEPS for cost effective prescribing of serotonin-norepinephrine reuptake inhibitors (SNRIs) in major depressive disorder: focus on venlafaxine (Effexor) versus duloxetine (Cymbalta).Ment Health Clin. 2013;3:100.
31. Composite list: All QT drugs Arizona Center for Education and Research on Therapeutics. http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs/. Accessed November 30, 2013.
32. Medical Letter Online. Levomilnacipran (Feztima): a new SNRI for depression. http://secure.medicalletter.org/TML-article-1432a. Accessed February 24, 2014.
33. Bose A,Gommoll C,Li H,Ruth A,Escher T.Levomilnacipran SR in the treatment of major depressive disorder: an analysis of efficacy data from 2 phase III studies. Paper presented at: 52nd Annual Meeting of the New Clinical Drug Evaluation Unit; Phoenix, AZ.
34. Montgomery SA,Mansuy L,Ruth A,Bose A,Li H,Li D.Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.J Clin Psychiatry. 2013;74:363-369.
35. Greenberg W,Li H,Gommoll C,Ruth A,Escher T.Levomilnacipran SR in the treatment of major depressive disorder: an analysis of safety and tolerability data from 2 randomized placebo-controlled trials. Paper presented at: 52nd Annual Meeting of the New Clinical Drug Evaluation Unit; Phoenix, AZ.
36. Shiovitz T,Greenberg WM,Chen C,Forero G,Gommoll CP.A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120 mg/day for prevention of relapse in patients with major depressive disorder.Innov Clin Neurosci. 2014;11 (1-2): 10-22.
37. Williams JB,Kobak KA.Development and reliability of a structured interview guide for the Montgomery-Åsberg Depression Rating Scale (SIGMA).Br J Psychiatry. 2008;192:52-58.
38. Sheehan DV,Harnett-Sheehan K,Raj BA.The measurement of disability.Int Clin Psychopharmacol. 1996;11:89-95.
39. Mago R,Forero G,Greenberg WM,Gommoll C,Chen C.Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.Clin Drug Investig. 2013;33:761-771.
40. SambunarisAGommollCChenCGreenbergWM. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analysis of five double-blind, placebo-controlled trials [published online March 27, 2014]. Int Clin Psychopharmacol. http://journals.lww.com/intclinpsychopharm/Abstract/publishahead/Efficacy_of_levomilnacipran_extended_release_in.99749.aspx. Accessed April 5, 2014.